Favorable outcome after physiologic dose of sodium-D,L-3-hydroxybutyrate in severe MADD.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 25246622.
- Also identified by DOI 10.1542/peds.2013-4254.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Multiple acyl coenzyme A dehydrogenase deficiency (MADD) is a severe inborn error of metabolism. Experiences with sodium-D,L-3-hydroxybutyrate (3-HB) treatment are limited although positive; however, the general view on outcome of severely affected patients with MADD is relatively pessimistic. Here we present an infant with MADD in whom the previously reported dose of 3-HB did not prevent the acute, severe, metabolic decompensation or progressive cardiomyopathy in the subsequent months. Only after a physiologic dose of 2600 mg/kg of 3-HB per day were ketone bodies detected in blood associated with improvement of the clinical course, N-terminal prohormone of brain natriuretic peptide and echocardiographic parameters. Long-term studies are warranted on 3-HB treatment in patients with MADD.
Medical subject headings
- 3-Hydroxybutyric Acid
- Multiple Acyl Coenzyme A Dehydrogenase Deficiency
- Severity of Illness Index